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Abstract
Immunizations are crucial to the prevention of disease, thus, having an accurate measure of 
vaccination status for a population is an important guide in targeting prevention efforts. In order to 
comprehensively assess the validity of self-reported adult vaccination status for the eight most 
common adult vaccines we conducted a survey of vaccination receipt and compared it to the 
electronic medical record (EMR), which was used as the criterion standard, in a population of 
community-dwelling patients in a large healthcare system. In addition, we assessed whether 
validity varied by demographic factors. The vaccines included: pneumococcal (PPSV), influenza 
(Flu), tetanus diphtheria (Td), tetanus diphtheria pertussis (Tdap), Human PapillomaVirus (HPV), 
hepatitis A (HepA), hepatitis B (HepB) and herpes zoster (shingles). Telephone surveys were 
conducted with 11,760 individuals, ≥ 18, half with documented receipt of vaccination and half 
without. We measured sensitivity, specificity, positive and negative predictive value, net bias and 
over- and under-reporting of vaccination. Variation was found across vaccines, however, 
sensitivity and specificity did not vary substantially by either age or race/ethnicity. Sensitivity 
ranged between 63% for HepA to over 90% (tetanus, HPV, shingles and Flu). Hispanics were 2.7 
times more likely to claim receipt of vaccination compared to whites. For PPSV and Flu those 65+ 
had low specificity compared to patients of younger ages while those in the youngest age group 
had lowest specificity for HepA and HepB. In addition to racial/ethnic differences, over-reporting 
was more frequent in those retired and those with household income less than $75,000. Accurate 
information for vaccination surveillance is important to estimate progress toward vaccination 
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coverage goals and ensure appropriate policy decisions and allocation of resources for public 
health. It was clear from our findings that EMR and self-report do not always agree. Finding 
approaches to improve both EMR data capture and patient awareness would be beneficial.
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1. Introduction
Because immunization is crucial to the prevention of disease, having an accurate measure of 
vaccination status for a population can serve as an important guide in targeting prevention 
efforts.[1,2] To monitor vaccination status, the United States conducts population-based 
vaccination coverage surveys, [3,4] however, obtaining accurate assessment is difficult. 
Most people have attended multiple medical practices, leaving records scattered or 
incomplete. Time may also result in lapses in memory [5–7]. Several vaccinations, such as 
tetanus/diphtheria (Td), pneumococcal polysaccharide vaccine (PPSV), hepatitis A (HepA) 
and hepatitis B (HepB) series, may have been administered years before a survey is 
conducted [6]. Also, patients may affirm receipt of vaccines they believe they should have 
obtained or deny obtaining a vaccination that might indicate risky behavior [8,9]. Lack of 
accurate data decreases the ability to interpret estimated coverage levels and may cause 
providers to miss opportunities to provide needed vaccines. Validity of self-report has been 
extensively studied for Influenza (Flu) and PPSV [9–15], but there is a paucity of literature 
on other vaccines (e.g., HepA, HepB) and relatively new vaccines such as Human 
Papillomavirus (HPV). Further, information on validity that is age and race/ethnicity 
specific has also had limited study [5,7,16]. In order to comprehensively assess the validity 
of self-reported adult vaccination status for the eight most common adult vaccines, we 
conducted a survey of vaccination receipt and compared it to the electronic medical record 
(EMR) in a population of community-dwelling patients in a large healthcare system. In 
addition, we assessed whether validity varied by demographic factors. The purpose of this 
paper is to report the concordance of data obtained through both methods of data collection.
2. Methods
2.1. Study setting and population
This study was conducted in an integrated health care delivery system with 21 primary care 
clinics, 30 specialty clinics and over 700 practicing physicians. The plan insures over one 
million people in an open-access system, allowing patients to obtain care within the medical 
group or the larger network. The vast majority of care is obtained within the network as 
nearly all services are covered. The majority of the population is white, employed, with 
education of high school or beyond. Eligible patients were 18 years or older as of January 1, 
2007, and seen in one of the medical clinics during 2007.
Health plan Institutional Review Board (IRB) approval was granted for the conduct of this 
study.
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The study was conducted in two phases. The first, was a retrospective review of the EMR 
data to determine documented receipt of vaccine. In the second phase, a telephone survey 
was conducted. Concordance of vaccination status between the EMR and self-report from 
survey results was assessed.
In Phase 1, EMR data were examined for patients seen in 2007. For HepA this timeframe 
was expanded back to 2001 to ensure adequate numbers of potential subjects. All 
vaccination information was obtained for each patient as far back as it was available. The 
denominator of those eligible for each vaccine was determined and a vaccine specific 
database was created. The eight vaccines studied included: PPSV, Flu, tetanus/diphtheria 
Td), tetanus/diphtheria/acellular pertussis: (Tdap), HPV, HepA, HepB and herpes zoster 
vaccine (shingles). Data were stratified by age group for most vaccines and by race/ethnicity 
for PPV and Flu.
Vaccination history was retrieved from information obtained from patients when they 
entered the health system, which was entered into the EMR as were vaccinations obtained 
within the system. A vaccination procedure code as well as the facility where it was 
obtained, lot number and vaccine manufacturer were considered evidence of vaccination. 
For each vaccine, the date of the most recent vaccination was recorded ensure we were using 
the most relevant information.
EMR data were sorted by vaccine and within each vaccine for the ages and racial/ethnic 
specific groups of interest to the Centers for Disease Control and Prevention (CDC). For 
surveys of PPSV, tetanus, HepA, and Flu vaccination, the age groups sampled were for 18–
49 years, 50–64 and 65+; for shingles (50–64 and 65+); HepB (18–49 and 50–64) and HPV 
(females 18–26). Specific racial/ethnic groups (White, Black, Hispanic) were targeted for 
those 65+ for the PPSV vaccine and all three age categories for Flu. For each group we 
determined the underlying EMR vaccination rate. We then sorted based on documented 
evidence of receipt of vaccination: those with and without. After creating all age and race/
ethnicity groups by receipt or no receipt of vaccine, there were a total of 56 sampling strata 
(Appendix A).
2.2. Patient survey
For Phase 2, the patient survey, we randomly selected 300 individuals from each strata, to 
ensure 200 completed surveys. Two weeks prior to initiating the telephone calls for a given 
strata, the EMR data was refreshed to be certain all vaccination information was current. 
Anyone with modified information was reclassified. Letters of invitation for participation 
were then sent to the 300 randomly selected individuals. There were up to 15 attempts to 
reach each patient by telephone. Surveys were conducted between January 2009 and March 
2011. The intention was to ask any individual about just one vaccine. However, in order to 
fill some strata (i.e. Hispanic 65+, Black 65+) 339 subjects were surveyed for more than one 
vaccine.
2.3. Survey content
Surveys were created for each vaccine. Subjects were asked if they “ever” received the 
vaccine in question. Responses were “yes”, “no”, “don’t know”, and “refused to answer.” 
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Follow-up questions varied by vaccine regarding how long ago the immunization was 
obtained. Subjects surveyed about tetanus vaccination were also asked if they were told if 
the vaccine contained pertussis (whooping cough). Specifics on all vaccines can be found in 
Table 2. The core content of all surveys was similar. Demographics included: age, sex, race/
ethnicity, marital status, education, employment and annual household income. We asked 
whether reported information was based on recall or if participants had records of 
vaccination status. Patients with no EMR documentation, claiming to have been vaccinated, 
were asked if they had any evidence. Some immigrants (<5%) had vaccination history cards.
2.4. Statistical analysis
Demographic characteristics were reported overall and by self-reported vaccination status. 
In order to assess the validity of self-reported vaccination status, we measured sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV). In 
addition, we assessed net bias and lack of concordance indicated by over-and under-
reporting of vaccination.
We calculated agreement statistics sensitivity, specificity, positive predictive value, and 
negative predictive value.[17] Additionally, we calculated a Kappa statistic,[18] to measure 
agreement between self-report and EMR (agreement was categorized as follows: almost 
perfect 0.81–1.00, substantial agreement 0.61–.80, moderate agreement 0.41–0.60, fair 
0.21–0.40, and poor <0.21). These validity parameters were calculated for all vaccines and 
for each vaccine separately. Clinically, if a patient can’t affirm that they have had the 
vaccine, a provider may offer the vaccine, thus we considered the lowest coverage scenario 
where all “don’t knows” for self-reported vaccination status were considered “no”.
Biased estimates can occur as a result of unequal sampling rates across strata. To correct for 
the unequal sampling rates of vaccinated and unvaccinated persons across sampling strata, 
all study data were weighted to reflect the actual distribution of EMR vaccination status 
among study-eligibles within each of the age and race/ethnicity-specific strata. Sampling 
weights were computed as the reciprocal of the achieved sampling fraction for each stratum. 
The weighted analysis results in numbers that sum to that of the original population. 
Statistical analyses of validity measures accounted for the complex sampling methods and 
weighting. All statistical analyses were conducted using SAS version 9.2 (SAS Institute, 
Inc., Cary, NC).
Net bias was calculated as the estimated vaccination coverage estimate (self-reported 
vaccination) minus the actual vaccination coverage estimate (EMR based). In order to 
compare vaccines with varying coverage levels, we also calculated net bias relative 
difference (estimated vaccination – actual vaccination)/actual vaccination) and multiplied by 
100 to get percent. In addition, we calculated proportions under- and over-reporting (1-
sensitivity and 1-specificity, respectively).
To test whether over- or under-reporting differed by patient characteristics (self-reported 
race/ethnicity, sex, age, marital status, employment status, education status, and income 
level) we conducted a series of logistic regression models using the entire survey sample for 
all eight vaccines to estimate odds ratios and 95% confidence intervals. For under-reporting, 
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we restricted the analysis to those who had EMR documentation of vaccination and modeled 
the likelihood of self-report of no vaccination as a function of patient characteristics one at a 
time. Because 339 subjects (<3%) were surveyed for two vaccines and all others were 
surveyed for only vaccine, we conducted a sensitivity analysis to see if the assumption of 
independence was violated. The logistic regression models examining over- and under-
reporting were run excluding the second observation recorded for each subject with more 
than one survey.
2.5. Additional follow up
To further assess the completeness of our data, we conducted a substudy. There were two 
groups where misclassification would be most likely to exist: those reporting having had the 
vaccination where we had no EMR record (the more obvious group) and those who had 
neither an EMR record nor self-report of vaccination. In the first group, we asked for any 
evidence of receipt of vaccination and if evidence was available, the patient was reclassified. 
For the latter group, we inquired if they might have any additional medical history 
elsewhere. We then asked for consent to allow us to check medical records outside our 
health care system. Resources were available to conduct this additional check for unrecorded 
vaccination on 330 patients. We were able to identify and follow up on 279 (85%) who met 
the required eligibility (no record in EMR, self-report of no vaccination, attended a clinic 
outside of those within the health system and gave permission to contact the outside clinic).
3. Results
The goal of 11,200 completed surveys was based on 200 each from the 56 strata. We ended 
with 11,760 completed surveys: 10,670 toward goal and 1090 over. The overage occurred 
due to an initial flaw in the tracking program affecting all HepA (overage = 713). Overage 
was also due to multiple interviewers continuing to survey until informed that the goal was 
achieved. For non-Hispanic blacks 65+ and Hispanics with no evidence of PPSV or Flu 
vaccination, numbers in the base population were insufficient to achieve our goal. Thus, 
although our intention was to survey each individual about only one vaccine, for certain 
strata we used an individual more than once. There were 339 (<3%) individuals who were 
surveyed about more than one vaccine. Over half of these were Hispanic.
Table 1 presents the demographic characteristics of the study sample. Because certain ages 
and race/ethnicities were dictated by the study, the balance is as expected. The fields 
dictated by the study protocol are shaded. The other variables are reflective of the health 
plan’s population.
3.1. Agreement statistics
The sensitivity of self-reported vaccination status for true vaccination status, based on EMR 
data, ranged between 63% (HepA) and over 90% (Td, Tdap, HPV, shingles and Flu). 
Specificity varied widely from 11% for Tdap and Td to 91% for PPSV. PPV varied from 
below 50% for Shingles, HepA and HepB to 80% for HPV. NPV was over 90% for all 
vaccines except tetanus (55%). When asked if their tetanus shot included the pertussis 
vaccine, 10% of those who claimed to receive tetanus vaccine said they received the 
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pertussis vaccine, 11% said no, 17% said the provider did not say, and the remaining 61% 
did not know.
EMR vaccine coverage based on the source population is shown in Table 2. Table 2 also 
presents net bias and net bias relative difference. Net bias estimates ranged from −0.8 to 
39.0 for PPSV and tetanus, respectively. Values for net bias relative difference ranged 
considerably across vaccines; from low (PPSV and HPV) to moderate (HepA, Flu) to high 
(tetanus, shingles and HepB).
Table 3 reports the agreement per vaccine for race/ethnicity and age strata. With the 
exception of PPSV, sensitivity did not vary considerably by age and/or race/ethnicity within 
vaccine strata. With regard to specificity, for PPSV, and Flu, those over 65 had low 
specificity compared to patients of younger ages. In contrast for HepA and HepB, those in 
the youngest group had the lowest specificity. Low specificity was also found with 
Hispanics for Flu vaccine. With some exceptions, NPV generally was high; however, for 
PPSV those over 65 had low NPV as did tetanus for all ages. PPV varied by age for PPSV, 
with those 65+ with the highest values and for shingles, those 50–64 were highest.
In order to examine differences in over- and under-reporting as a function of patient 
characteristics combined across all vaccines, we conducted logistic regression adjusted for 
age and sex (Table 4). Compared with those ages 18–49, those 50–64 had a slightly lower 
odds of under-reporting. Black subjects and those reporting other race/ethnicity had 3-fold 
higher odds of over-reporting, but no association was observed with under-reporting. 
Hispanic subjects had a 4-fold greater odds of over-reporting and had 60% lower odds of 
under-reporting compared with whites. Retired subjects had higher odds of over-reporting 
and lower odds of under-reporting compared to those working/homemaker/or student. Those 
with household incomes below $75,000 were more likely to over-report and less likely to 
under report compared with those making $75,000 or more. Compared with those who 
reported some college, those with a high school diploma or less were 2.3-fold more likely to 
over-report. We did not observe strong associations of over- or under-reporting by marital 
status.
In addition, we conducted a sensitivity analysis to see if over-or under-reporting differed 
when we excluded the second observation for the subjects who were surveyed for more than 
one vaccine. For this series of analyses, the odds ratios for each demographic characteristic 
were similar except for gender, where in the sensitivity analysis for over-reporting males 
had higher odds of over-reporting compared to females.
3.1.1. Additional follow up patients—For the 279 patients who had no record in EMR 
of vaccination, self-report of no vaccination, attended a clinic outside the system and gave 
permission to contact the outside clinic, we were able to obtain information on 246 (88%). 
Of the 246 total patients with information obtained outside of our system, 8 were found to 
have received vaccinations (3%). Three of the 8 vaccinations were for PPSV, two for 
shingles and one each for Tdap, Td and HPV.
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3.2. Sensitivity analyses
While we report the results of the lowest coverage scenario by counting “don’t know” 
responses as “no”, we conducted additional sensitivity analyses (data not shown). We 
compared the effects on validity measures when all “don’t know” responses were considered 
“yes” and found sensitivity improved slightly and specificity measures decreased slightly for 
all vaccines except Flu, for which measures of sensitivity and specificity were virtually the 
same.
4. Discussion
The purpose of this study was to examine self-reported vaccination status compared to EMR 
data. Considerable variation was found by vaccine, age and race/ethnicity. We also assessed 
rates of under-and over-reporting and net bias. Under-reporting was relatively low, except in 
the Hispanic strata, while over-reporting varied by vaccine. The net bias relative difference 
also varied widely. We found more favorable agreement statistics for PPSV and HPV. 
Tetanus had the largest net bias relative difference.
Findings on sensitivity, specificity, PPV and NPV, were consistent with the literature [9–
15]. Flu studies have reported higher sensitivity with lower specificity [9–11,13]. In a recent 
study, however, examining the accuracy of Flu vaccination from four Vaccine Safety 
Datalink sites, sensitivity ranged from 0.51–0.89, highest in those ages 65–79 and those at 
high risk [8]. While our findings for those age 65+ were also highest (96% versus 89% for 
age 18–49), specificity was the lowest of all age groups (50% versus 68% for those 18–49). 
Findings for PPSV vaccination have been reported as more variable, perhaps due to more 
distant recall [14,19].
The self-report accuracy of HepB vaccination has been poorly studied. One study using 
serological data found self-report to be unreliable [20]. However, others examining self-
report of Flu, tetanus booster, and HepB found patient questionnaire nearly as sensitive and 
specific (hepatitis B: sensitivity 80%, specificity 100%) as the medical record [12]. Our 
findings were a bit lower for HepB specificity (sensitivity 0.73, specificity 0.67). HepB is 
administered primarily for employment or as a travel vaccine with a number of other 
vaccines, and no boosters, so recall may be difficult.
Inaccurate patient reporting has implications for both clinical care and estimates of 
vaccination coverage [1,2,8,21]. A positive net bias in vaccine coverage level estimates may 
indicate better progress toward disease control and achievement of national and local health 
objectives than is true.
Our patients were not asked to distinguish between Td/Tdap so we collapsed them for 
examination; the reason for the low specificity is unclear. Perhaps the 10-year duration 
between vaccinations forTd and newness of Tdap is part of the explanation. If a tetanus 
vaccination was given several years ago it is possible it was administered before the patient 
entered our healthcare system and they did not report it upon intake into the system.
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4.1. Limitations
This study has several potential limitations. First it was conducted in a single health plan so 
findings may not be representative of other populations. Further, survey participants may 
differ from non-participants, although we did select a random sample from each strata. For 
some vaccines, the EMR may not always have gone back as far as needed, leading to some 
misclassification. In addition, it is possible that patients may have obtained vaccinations 
outside of the health system, particularly for the Flu vaccination which is commonly 
available in work and retail settings [22,23]. If patients did not report obtaining these to a 
provider, they would be missed. Our overall findings for the shingles vaccine should be 
taken with caution, as we surveyed ages 50 and over and the Adsvisory Committee for 
Immunization Practices recommendation for obtaining this vaccine starts at age 60 [24]. 
Thus, because of differences in study population, survey question wording, recall period and 
other methodological differences, results from this study may not be comparable to self-
reported data from other surveys such as the National Health Interview Survey [25].
Despite its limitations, the assessment of the accuracy of self-report using telephone survey 
for each of the vaccines studied is a major strength of the study. The population was large, 
with demographic data and robust vaccination histories. This enabled us to examine self-
report by age and race/ethnicity. The comprehensive medical record allowed the team to 
readily identify the underlying populations of interest, obtain documented vaccination data 
on all and compare self-report to EMR. The presence of vaccination in the EMR provided 
strong evidence that vaccination had occurred, although lack of documentation did not 
guarantee that no vaccination had been obtained. Few studies have tested the accuracy of 
telephone survey self-report for many of the vaccines studied. While Flu and PPSV have had 
extensive study, limited data exists on the newer shingles or the HPV vaccinations. Our 
study adds to our understanding of well-reported vaccination coverage as well as reporting 
on lesser-studied vaccinations.
Accurate information for vaccination surveillance is important to be able to estimate 
progress toward Healthy People 2020 vaccination coverage objectives and to ensure 
appropriate policy decisions and allocation of resources for public health. It was clear from 
our findings that EMR and self-report do not always agree. Finding approaches to improve 
both EMR data capture and patient awareness would be beneficial. The EMR may not 
always be accurate if vaccination occurred in the past. It is also possible that vaccines 
obtained outside the system are not getting captured. With growing number of pharmacies 
offering vaccinations, health system records may become less trustworthy. According to Sy, 
if there is no record in data base, there is a 20% chance that vaccination was obtained in a 
different setting [2]. Assisting patients to improve recall would also be advantageous. Like 
others, we found higher rates of over-reporting compared to under-reporting [5]. With 
today’s technology it is possible to have patients record their vaccinations into personal 
devices and electronic applications. Information from such applications could be part of 
inquiry at office visits, similar to updating address and telephone number information. The 
portability of the EMR and immunization registries could also facilitate improved accuracy 
of vaccination status.
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5. Conclusions and future directions
Health system electronic databases provide ready capture of data on vaccinations, yet 
potential for misclassification cannot be ignored. As more vaccines are available in non-
traditional settings, this problem is likely to become more common. We must continue to 
find ways for both health plans and patients to capture and communicate information on 
vaccination status to ensure surveillance efforts are as robust as possible.
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Appendix A. Vaccine target groups and eligibility status
Vaccine Age groups Race/ethnicity groups Additional eligibility criteria
Pneumococcal (PPV) 65+ White
Black
Hispanic
50–64 All races Forages 18–64: patients with risk factors: American 
Indian or Alaska Native; history of diabetes, lung 
disease, heart disease, kidney disease, liver disease, 
anemia spleen (including sickle-cell disease), 
cancer, immunodeficiency (HIV/AIDS), organ 
transplant, rheumatologic diseases (treatment 
involved taking steroids), alcoholism, splenectomy, 
spinal fluid leak
18–49
Influenza (LAIV/TIV) 65+
50–64
18–49
White
Black
Hispanic
Tetanus (Td)
Tetanus (Tdap)
65+
50–64
18–49
All races
HPV 18–26 All races Females only
Hepatitis A 65+ In addition to those seen in 2007, we included those 
who had a diagnosis of liver disease or Hemophilia 
or took a Hepatitis A laboratory test at one of owned 
clinics during 2001–2007.
50–64 All races
18–49
Hepatitis B 50–64 All races Patients with risk factors which include: Asian or 
Pacific Islander ethnicity, history of a sexually-
transmitted disease, kidney disease, liver disease, 
hemophilia, Immunodeficiency (including HIV/
AIDS).
18–49
Shingles 65+
50–64
All races
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Table 4
Odds ratios and 95% confidence intervals in the relationship of patient characteristics with over-reporting and 
under-reporting.
Over-reportinga,c N = 6074 Under-reportingb,c n=5686
Gender
 Female 1.0 REF 1.00 REF
 Male 1.56 (1.22–2.01) 1.16 (0.99–1.36)
Age(%)
 18–49 1.00 REF 1.00 REF
 50–64 0.85 (0.64–1.14) 0.61 (0.54–0.70)
 65+ 1.10 (0.83–1.47) 1.13 (0.99–1.30)
Race/ethnicity
 Non-Hispanic white 1.00 REF 1.00 REF
 Non-Hispanic black 3.37 (2.26–5.01) 0.92 (0.70–1.21)
 Hispanic 4.00 (2.53–6.32) 0.40 (0.21–0.74)
 Other 2.90 (1.80–14.69) 1.67 (1.21–2.30)
Educational attainment
 HS grad or less 2.28 (1.68–3.09) 0.92 (0.76–1.12)
 Some college or college grad 1.0 REF 1.00 REF
 More than college 0.83 (0.60–1.15) 0.98 (0.80–1.20)
 No data 1.61 (0.32–8.19) 2.17 (0.88–5.40)
Employment status
 Working/homemaker/student 1.00 REF 1.00 REF
 Unable to work, can’t find work 2.10 (1.39–3.19) 1.04 (0.78–1.38)
 Retired 1.17 (0.78–1.75) 0.65 (0.51–0.82)
 No work data 0.68 (0.12–3.91) 2.23 (0.75–6.59)
Marital status
 Married/couple 1.0 REF 1.00 REF
 No longer married 1.40 (1.00–1.94) 0.71 (0.48–1.06)
 Single 1.42 (0.99–2.04) 0.73 (0.47–1.14)
 No data 1.93 (0.56–6.64) 0.44 (0.11–1.72)
Household income
 <$75,000 1.74 (1.28–2.38) 0.80 (0.66–0.96)
 ≥$75,000 1.00 REF 1.00 REF
 No data 2.09 (1.44–3.01) 0.85 (0.68–1.07)
a
Models restricted to those with EMR documentation of vaccination.
b
Models restricted to those with no EMR documentation of vaccination.
cAll models adjusted for sex and age.
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